Cure My Disease

Don't miss your cure!

 Log in / Sign up

Targeted radiation zaps glioblastoma cells after surgery

NCT ID NCT05533242

Ongoing Disease control Sponsor: University Hospital Muenster Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new treatment for glioblastoma, an aggressive brain cancer. After standard therapy (surgery, chemo, radiation), a radioactive antibody is injected into the brain cavity to target remaining tumor cells and delay recurrence. The study enrolls 15 adults and focuses on finding the safest dose and measuring how radiation spreads in the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOM WHO GRADE 4 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOM WHO GRADE 4

Contacts and locations

Locations

  • Klinik für Allgemeine Neurochirurgie des Universitätsklinikums Köln

    Cologne, 50937, Germany

  • Klinik für Neurochirurgie des Universitätsklinikums Essen

    Essen, 45147, Germany

  • Klinik für Nuklearmedizin der Universität Münster

    Münster, 48149, Germany

  • Klinik für Nuklearmedizin des Universitätsklinikums Köln

    Cologne, 50937, Germany

  • Klinik für Nuklearmedizin, Strahlenklinik des Universitätsklinikums Essen

    Essen, 45147, Germany

  • Universitätsklinikum Würzburg - Neurochirurgie

    Würzburg, 97080, Germany

  • Universitätsklinikum Würzburg - Nuklearmedizin

    Würzburg, 97080, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.